The complaint was lodged by Mumbai-based Express Industry Council of India, which represented major express courier and cargo companies such as DTDC, Aramex India, Blue Dart, DHL Express, GATI and First Flight.
FDA had also issued warning letters to Ranbaxy's Paonta Sahib and Dewas facilities as it found extensive problems and deviations from manufacturing norms.
There may be shortage of drugs till pharmaceutical companies supply new batches with revised MRPs.
Apollo Pharmacy, the country's largest branded drug retail network with over 1,500 outlets, has temporarily suspended sale of medicines manufactured by Ranbaxy Laboratories. It has also stopped further procurement from the company for now.
Says inordinate delay on this and other issues raised by firm earlier are impacting investor confidence.
The 2008 deal agreement contains provisions of arbitration to be held in that country.
Consultants are working with various teams on manufacturing, R&D, etc, to assess per-month productivity of each department.
The trouble-stricken company has sought appointment with at least two major hospitals -- Mumbai-based Jaslok and Gurgaon-based Medanta Medicity.
The company was indicted for violations at one of its US facilities in 2009, even after Daiichi Sankyo took over as majority shareholder in 2008.
The US FDA, during its inspection of Ranbaxy's manufacturing facilities in India, between 2006 and 2008, had found violations, incomplete testing records and an inadequate stability programme, besides manufacturing practices that did not follow regulations.
Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
Singh says Japanese pharma giant's allegations false.
Bajaj talks about his plans for the RE-60, which was showcased in January last year in the Auto Expo, to Business Standard.
Sahara will save Rs 400 crore (Rs 4 billion) annually by pulling out IPL team Pune Warriors India and not re-bidding for national team sponsorship.
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
DoT's proposal to impact many, including Vodafone
Unlike Malaysia where the airline did not have competition from other LCCs, its new market in India has quite a few thriving players, making it a late entrant.
It has sought the permission of the Foreign Investment Promotion Board to start single-brand retail outlets.
Dinesh Thakur says he waved the red flag only after Ranbaxy didn't respond to his concerns.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances